Having trouble viewing this email? View in your browser.
ESCMID Logo

26 September 2017
WEEKLY NEWS

Dear colleagues,

Several ESCMID representatives contributed to a new report published by WHO, which found very few potential treatment options for the most threatening antibiotic-resistant infections. The core report is complemented by an updated document describing their priority pathogen list.

EITaF published new commentaries on its webpage about the ECDC report, detailing clusters of autochthonous chikungunya cases in Rome and Anzio (Italy), and the new European Medical Corps.

This is the last week to apply for the Medical Guidelines Director position at ESCMID. Qualified candidates are invited to send their application to ESCMID’s Publications and Communications Officer, Murat Akova, before 30 September 2017.

 

Registration for ECCMID 2018 in Madrid is open now!

The registration for ECCMID from 21 – 24 April 2018 in Madrid, Spain, is open now. An early-bird registration fee is available until 25 January 2018, by which date you will also know if the abstracts you have submitted have been accepted. We currently have more than 200 confirmed faculty, and the ECCMID Programme Committee is currently working on the schedule of the invited programme, which once again promises to feature top-notch keynote lectures, sessions and symposia complementing the abstract presentations.

› Read more
 

CMI highlight: evaluation of new Mycoplasma genitalium assay

Unemo et al investigated the increasing resistance of Mycoplasma genitalium (MG) to current first- and second-line treatment (azithromycin and moxifloxacin resp.) and estimated the prevalence of MG, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) in 5,269 patients located in Denmark, Sweden and Norway. First, they compared the sensitivity and specificity of the new Aptima CE/IVD AMG test, with that of the MG Alt TMA-1 test and mgpB qPCR for pathogen detection. Sensitivity ranged between 99.13-100%, 99.13-100% and 73.24-82.60% respectively; the specificity ranged between 99.57-99.96%, 100% and 99.69-100% respectively. Second, they found the prevalence of MG infection was 7.2% (382/5269); that of azithromycin and moxifloxacin resistance-associated gene mutations was 41.4% (120/290; 17.7%-56.6%) and 6.6% (18/274; 4.1-10.2%) resp. The prevalence of CT and NG over the entire patient group was not given. The authors emphasized the importance of using validated and quality-assured molecular tests for MG detection, routine testing of MG-positive samples as well as surveillance of antimicrobial resistance.

› Read more
 

Presentations from Vaccine Conference in Dubrovnik available now

The large majority of the presentations from the successful 4th ESCMID Conference on Vaccines from 8 – 10 September 2017 in Dubrovnik, Croatia, are now available on the ESCMID eLibrary. More than 100 participants from over 33 different countries attended the congress. The scientific programme for the conference was developed in cooperation with the European section of the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC). About 40 internationally renowned experts presented and discussed topics such as the in the management of viral diseases, including Zika or Ebola, as well as new vaccines and efforts to eradicate older diseases including polio.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.